Neuronetics (STIM) Set to Release Earnings on Wednesday

Neuronetics (NASDAQ:STIM) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Neuronetics to announce earnings of ($0.08) per share and revenue of $40.42 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.07. The firm had revenue of $41.57 million for the quarter, compared to analysts’ expectations of $40.17 million. On average, analysts expect Neuronetics to post ($0.33) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Neuronetics Stock Performance

Shares of NASDAQ STIM opened at $2.19 on Wednesday. The stock’s 50 day moving average price is $2.57 and its 200-day moving average price is $1.87. Neuronetics has a twelve month low of $0.80 and a twelve month high of $3.44.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a report on Tuesday, July 21st. BTIG Research reaffirmed a “buy” rating and set a $6.00 price objective on shares of Neuronetics in a report on Thursday, September 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Monday, September 14th. Finally, B. Riley Financial began coverage on shares of Neuronetics in a research report on Friday, September 11th. They set a “buy” rating for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Neuronetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Insiders Place Their Bets

In other Neuronetics news, major shareholder Jorey Chernett bought 14,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $3.16 per share, for a total transaction of $44,240.00. Following the acquisition, the insider owned 10,602,988 shares in the company, valued at approximately $33,505,442.08. This represents a 0.13% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 8.40% of the stock is currently owned by insiders.

About Neuronetics

Neuronetics, Inc is a medical technology company that develops and commercializes noninvasive treatments for psychiatric and neurological disorders. Its primary product is NeuroStar TMS Therapy, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain associated with mood regulation.

NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for treating major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and depression with anxious distress.